elast upgrad ow
believ proprietari novaseq custom survey provid answer
critic question thesi critic time substanti
elast demand custom adopt novaseq system
provid visibl multipl year double-digit growth
better convict durabl revenu growth upgrad
overweight ew rais price target
novaseq adopt signific demand novaseq expect major
custom transit toward platform survey focus largest
research custom self-report total budget million
revenu novaseq instal base custom spoke expect
doubl today next year novaseq addit
go replac least instrument across board signific
reduct hiseq instrument hiseq
 volum growth novaseq custom survey expect substanti increas
volum sequenc next two year
 budget growth respond project weight average budget growth nobodi
expect decreas weight average spend per novaseq survey
view long-term target model project end
model valuat demand elast increas convict
sustain double-digit revenu growth high-teen better earn growth
specif highlight nascent opportun clinic diagnost china
target repres ep lt growth
pleas join us today et confer call discuss takeaway
proprietari novaseq custom survey well upgrad
overweight dial-in passcod pleas also join us
et tool time featur gener sequenc
view broad institut dial-in passcod
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight
rais usd
return equiti ttm
link barclay live interact chart
overweight leader next
gener sequenc project
signific growth driven larg research studi
nascent opportun clinic diagnost
signific competit moat rel
competit given brand scale
growth forseeabl futur
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ep
growth ultim depend
custom fund includ govern grant
nih well clinic reimburs lower
downsid case reflect downsid
ep
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
upgrad pivot point novaseq cycl provid multi-year view adopt
elast demand matter
action upgrad illumina overweight pt
confer call et takeaway proprietari novaseq survey
confer call et tool time industri expert call gener
sequenc view broad institut
see catalyst clinic substanti market opportun
keep level innov high continu drive elast demand
 domin clinic sequenc opportun
substanti elast
demand custom
adopt novaseq
system provid
visibl multipl year
double-digit growth
believ proprietari novaseq custom survey provid answer critic
question thesi critic time substanti elast
demand custom adopt novaseq system provid
visibl multipl year double-digit growth better convict
durabl revenu growth upgrad overweight
equal weight rais price target
upgrad pivot point novaseq cycl provid
multi-year view adopt
believ novaseq custom survey provid uniqu perspect
adopt system impact work largest genom center
absolut pivot time adopt curv platform perform
custom interview march may one year introduct
novaseq market believ time critic custom better sens
budget dedic system well expect
novaseq addit well decommiss platform sever uniqu
characterist survey believ import thesi
survey focus largest research custom
collect estim custom survey total budget
around million overal revenu given profil
custom believ serv use baromet research
 given multi-year adopt cycl novaseq believ result
survey provid glimps sustain consum growth
next sever year approxim hiseq hiseq
instrument place global estim everi novaseq replac
platform time given novaseq placement rate
instrument per year impli novaseq placement sustain
though believ like next gener high-
throughput platform point custom view survey
system addit de-commiss util volum growth elast demand
competit environ repres norm next year
addit demand elast novaseq bode well futur high-
throughput platform launch compani histor weve
concern novaseq could cannib exist consum stream
hiseq hiseq platform given replac cycl novaseq drive
demand elast believ futur high-throughput platform well
 convict elast demand allow research custom drive
continu growth miss piec puzzl improv
convict overal double-digit revenu growth clinic translat
sequenc rev one-way rapidli grow train view rapid
growth expect long time driven access test demand test due
push toward person medicin reimburs addit
believ long-term push toward broader panel also drive demand illumina
sequenc technolog given platform scalabl unmatch qualiti
versu peer final believ china region rev sustain
contributor growth compani embark person medicin initi
tout path
genom time
given dramat reduct
sequenc cost
paramount demand
grow faster rate drive
overal revenu growth
sequenc genom
elast demand matter
rel life scienc tool brethren next gener sequenc platform
uniqu technolog success driven abil drive price
point sequenc advanc technolog make much cost-effici
sequenc today first human genom sequenc billion
period gener sequenc
method
commerci lead faster cheaper accur genom
sequenc rapid advanc sequenc capabl also transform
deliveri genet analysi shift larg genom center toward clinic lab
genet sequenc reach point sequenc consid
routin drive new opportun genet test previous perceiv
unachiev believ growth driven demand target human genom
sequenc well industri outsid medic field
method revolution way research perform
sequenc use compani proprietari sequencing-by-synthesi methodolog
power come abil run test parallel massiv scale significantli
shrink amount time cost take sequenc genom shown chart
nation genom research institut cost sequenc singl
genom plummet approxim million use
illumina hiseq launch novaseq averag cost per genom
reduc roughli tout path time
given dramat reduct sequenc cost time paramount
sequenc demand grow faster rate price reduct drive overal
revenu growth believ report help provid visibl elast
demand real key debat thesi
survey includ head
largest
sequenc center
spend million
largest custom
interview eleven illumina novaseq custom march-may custom
purchas least novaseq system includ head
largest sequenc center world collect custom
novaseq hiseq platform repres respect
instal base collect self-report budget center
million around revenu combin factor make us
believ critic enough mass make call novaseq adopt cycl
four custom self-report spend million largest
custom report spend around million report refer respond
custom pie chart give sens rel size
 made strateg pivot servic provid toward becom bioinformat
provid longer own instrument sold anoth lab includ
commentari survey sinc believ use includ perspect
platform opportun genom univers posit
represent rel size custom survey mm
action upgrad illumina overweight pt
given feedback research elast demand coupl growth
opportun clinic china market upgrad overweight
increas price target price target repres
adj ep forecast target multipl base histor ratio
earn growth project high-teen forseeabl futur prior price
target repres prior ebitda forecast billion
prior adj ep forecast
confer call et takeaway
pleas join us today et confer call discuss takeaway
proprietari novaseq custom survey well upgrad
confer call et tool time industri
expert call gener sequenc view
broad institut
pleas also join us today et latest instal tool time
featur gener sequenc view broad
guest speaker dr niall lennon senior director translat genom product
detail pleas join us confer call dr niall lennon discuss latest
trend gener sequenc impact industri broad
institut launch mit harvard improv human health use
genom advanc understand biolog treatment human
diseas institut one largest genom sequenc center world
import custom confer call well discuss
elast demand sequenc fund environ genom research
new popul sequenc initi us us program
potenti sequenc move clinic set new technolog platform
illumina novaseq potenti long read sequenc technolog
speaker biographi dr niall lennon senior director translat genom
product develop broad institut mit harvard also
institut scientist overse evalu potenti disrupt genom
technolog applic basic research clinic research clinic
diagnost lennon broad sinc contribut
develop applic everi major massiv parallel sequenc platform
across rang field lennon also built clia/cap licens clinic laboratori
broad facilit return result patient support clinic trial
receiv ph pharmacolog univers colleg dublin complet
postdoctor studi harvard medic school massachusett gener hospit
novaseq adopt recur theme heard custom desir
work market leader interest stay forefront
innov system flexibl cost advantag platform
sever custom highlight signific cost advantag run exom vs hiseq
platform one custom call new xp protocol kit subdivid flow cell
greater flexibl clearli domin research market sequenc
feedback custom adopt novaseq
customerwhi adopt race nation center want stay date latest technolog even difficult find money need stay race versu old technolog high-throughput sequenc quicker cheaper time come market new machin center size discount consider cost throughput advantag peopl high throughput sequenc becom brainer much sequenc novaseq flexibl everyth whole genomesbnhgri expect larg genom center move novaseq partli cost reason also data slightli differ come hiseq next round fund larg genom center depend like play game cnovaseq platform futur drive continu develop platform longer look drive cost hiseq instrument move headphon port grumbl know need adopt new technolog dnovaseq great news compani high capac fewer instrument favor econom reflect path platform take fda design kit nextseq best version choic novaseq high-throughput platform choic project cog similar nextseq sever benefit enabl transit assay model product nextseq need product line ad capac novaseq put capac custom whole exom assay ecustom alreadi sold novaseq made strateg pivot becom bioinformat servic provid like perform machin user interfac qualiti data saw effici everyth someth extraordinari novaseq great partner fplatform futur huge decreas price novaseq run effect center move toward whole genom sequenc gthink novaseq cheaper genom vs big windfal whole exom sequenc reduct cost vs hiseq sequenc great thing novaseq eas use like load printer past person manag hiseq person manag twice mani novaseq admittedli eas use goe hand hand loss flexibl address one lane flow cell give much greater degre flexibl goe flow cell novaseq optim one batch sampl across entir novaseq flow cell hlike flexibl novaseq system abil run differ flow cell chip flow cell differ sequenc design flexibl novaseq transform system ground-break platform instrument xp protocol kit sub-divid flow cell sub-divid lane respect that use transform lane run uniqu librari type jspeed cost sequenc increas throughput need addit fund purchas second instrument next month kthe novaseq huge multipli capac focus fill barclay inc
believ novaseq
addit replac least
instrument across
signific demand novaseq expect major custom transit
toward platform custom spoke broadli expect decommiss
hiseq hiseq instal base novaseq addit replac least
instrument across board shown novaseq instal base
custom spoke expect doubl today next
year expect lead signific reduct hiseq instrument
hiseq instrument collect decreas one custom transit
fleet nextseq onto novaseq instrument interestingli speak one
custom alreadi sold two novaseq anoth lab made
strateg pivot focu bioinformat cater custom buy novaseq
proprietari novaseq custom survey show major transit toward novaseq platform
amongst center survey major chang remain instal base expect
novaseq custom survey expect substanti increas volum
sequenc next two year driven larg popul sequenc studi
increas cost effect exom sequenc substanti excit
around larg popul sequenc project sever referenc includ nih
us million genom initi us uk genom initi exom
grail liquid biopsi clinic trial could sequenc genom
regeneron announc would sequenc exom biobank
next month build volum total center survey describ
impli increas genom increas
exom collect number sampl
sequenc would increas anoth
custom proprietari survey expect volum growth
feedback custom expect volum growth
customerwhat expect volum growth aplan doubl tripl capac novaseq go novaseq limit govern money depth coverag go chang far whole genom concern coverag bvolum ramp huge amount grant center common diseas genom move year time center bought hiseq cluster slate genom depend us project want first year distribut across differ place could add genom year project hope million genom march pre-pr announc us came went see dean gave us permiss buy novaseq go us program feet cobvious would excit appli someth like bullish capabl suitabl award one two center would sequenc genom year period current capac novaseq could theoret sequenc genom per year institut look project context work get award dsampl grow reveu growth sampl tripl volum go whole exom sequenc effort next year signifc upsid potenti whole genom remain rel flat hit peak go rest commun observ steadi declin whole genom sampl number past month simpli exhaust biobank sampl avail sequenc current cost hexpect around sampl year robust growth thereaft acquir novaseq iramp novaseq today full capac gener genom jmostli rna sequenc remaind split across genom exom divers sequenc center kthink volum increas abl drive greater volum better price barclay illumina inc
custom survey expect weight averag budget increas
custom expect budget declin next year broad
rang expect growth matur center project growth
rapidli grow sequenc custom project growth one smaller
research custom cite flat budget use novaseq cost save drive offset
amount volum coverag driver sequenc growth almost everi
custom use depth everi custom expect spend least million per
year consum novaseq weight averag million
believ unlik actual attain level overal instal base
averag sinc new custom addit drag overal novaseq averag
model project million novaseq util per instrument end
result self-report back envelop math suggest
decent approxim compar net instrument add decommiss
project novaseq util would suggest custom survey
increas consum spend gb sequenc
estim custom proprietari novaseq survey increas sequenc spend
utilizationrev mmpull-through per inst per gbinstal base revsgb seq mm instal base revsgb seq mm revsgb yeary/i chang barclay illumina inc
feedback custom novaseq util
feedback custom elast demand
customerwhat view novaseq system util anovaseq take full work sequenc money spent go novaseq budget novaseq budget euro budget novaseq impli euro per per genom novaseq hope get least genom per year across novaseq grant would much bigger product would around number impli per per genom across novaseq genom impli around per novaseq consum cog revenu intend novaseq platform garound novaseq sampl per year flow cell genom per flow cell flow cell per run per run run per week genom per instrument per week useabl week genom per year per year max util hwe estim around reagent cost euro per sampl run expens use smaller instrument like miseq librari see proport sequenc sampl go ahead novaseq flow cell genom coverag per flow cell run flow cell back back hour run genom run week genom week center novaseq expect whole genom throughput per year lower cost lead higher spend novaseq brought expect get run least capac might human genom plant work jexpect volum increas per year kwill hard switch volum onto novaseq platform need buy robot autom order oper equip spend illumina consum shift onto novaseq platform get reduct price expect drive addit volum keep spend flat customerwhat view elast sequenc demand amor money illumina grow grow genom growth overal budget grow number sequenc grow sequenc cheaper captur market abil spend absolut fund bconsum growth similar budget growth use flow cell cost per genom slightli less current labor cost less total cost end less reagent consum lot less hiseq run hiseq xs alreadi best price overal budget growth nih fund histor flat decreas prodigi peopl worri flat stay largest growth come industri collabor that grow aggress expect sequenc consum grow line overal budget spend shift around small amount reduc cost sampl prep/sequenc sampl overal spend end around reduct alter data qualiti sequenc somewhat flat unlock small amount depend larg scale project good clinic busi grow sampl per year complic depend natur work your hown novaseq consid buy icent anticip spend grow per year jthe time grant impact overal budget growth overal import one horizon kthink price come roughli lower novaseq replac offset work barclay illumina inc
commentari increas
spend
grow exposur clinic
translat custom
china region increas
convict
see catalyst clinic substanti market
believ recent nation coverag determin ncd next gener
sequenc diagnost help pave pathway better clinic adopt
sequenc favor fda-approv product coverag drive
demand sequenc ncd specif call reimburs fda-
approv companion diagnost cdx use technolog inform treatment
decis patient advanc form cancer adopt broader clinic panel
play directli strength time vs peer technolog work better
smaller panel given view research market sustain posit growth
clinic growth anywher drive overal revenu growth
sensit analysi overal revenu growth research vs clinic growth
broad approv follow parallel review conduct fda
specif foundat medicin cover foundationon cdx test
result ncd three addit test receiv coverag includ foundat
illumina praxi extend ra panel leverag fda approv pma
clearanc process ensur test question appropri level
clinic analyt valid broad natur ncd oppos provid
coverag individu assay design spur innov among diagnost test
manufactur laboratori
view ncd show sentiment toward valu clinic
applic improv decis repres posit diagnost compani
develop cdx test design taken fda approv clearanc process
upon approv test immedi receiv medicar coverag
immedi posit implic thermo fisher newli cover
test believ decis benefici futur success
myriad cdx program variou on-going ngs-base cdx program
alway intent take potenti test fda myriad
decis implic compani cdx partnership leverag mychoic
hrd believ decis ultim act barrier entri laboratori
develop test ldt run cdx lab academ institut
 translat growth sale research growth rev believ research market sustain msd growth given posit nih fund deeper ngs/genom penetr spend believ clinic market sustain growth volum adopt broader panel combin factor drive anywher annual revenu growth togeth research clinic sequenc improv convict sustain double-digit revenu growth barclay inc
assum test meet patient elig requir detail figur
coverag test remain discret medicar administr
contractor order receiv coverag ncd list sever requir
patient test detail chart
survey clinic lab director shown recent increas interest
adopt laboratori thermo fisher led term respons
share gain respons survey respect follow
histor sever challeng lab look adopt clinic
includ adequ reimburs abil purchas suppli
singl vendor abil interpret result robust bioinformat technician
expertis run equip decentr manner enough volum
justifi invest believ ncd could drive barrier
reimburs acceler volum demand clinic improv
technolog platform eas transit laboratori pleas see full survey
publish tool dx lab survey say pama concern high dx
gain share vs lose share expect barclay lab director survey
believ china long-term structur growth driver life scienc
research sequenc fit natur countri ambit tackl long-term
societ need transit industri economi servic economi
better compet market china repres
revenu dwarf larger economi like unit state europ
said market experienc signific growth
believ market sustain growth next sever year
eclips billion revenu
requirementspatientspati -either recurr relaps refractori metastat advanc stage iv cancer -either previous test use test primari diagnosi cancer repeat test use test new primari cancer diagnosi made treat physician -decid seek cancer treatment -base laboratori test test -fda approv clearanc companion vitro diagnost -an fda approv clear indic use patient cancer -result provid treat physician manag patient use report templat specifi treatment option vs loss share respons lose share respons barclay illumina inc
expect china drive substanti growth number year
background sequenc capac larg came on-line china januari
bgi purchas hiseq time estim bgi
sequenc capac rest world combin bgi complet
acquisit complet genom use compani technolog develop
high-throughput sequenc capabl sequenc whole genom
compani revoloc system launch june commerci
halt novemb bgi decid consum genom subsidiari would
focu new benchtop sequenc prior revoloc delay
compani three order system
januari chines academi scienc ca first unveil chines
precis medicin initi pmi plan total fund estim
billion billion plan confirm nation peopl congress
meet march initi align china increas focu healthcar
demonstr countri commit becom leader precis medicin
fund go privat entiti well govern organ use
sequenc infrastructur data collect data interpret develop
associ diagnost biopharmaceut enabl decreas cost
requir sequenc whole human genom chines pmi aim advanc
person medicin analysi data million genom provid
high-throughput sequenc instrument stand benefit
chines pmi goal initi sequenc whole genom quickli larg
scale compani novaseq hiseq platform design
research center outfit sequenc instrument believ illumina
provid choic
assembl larg amount data peopl world initi aim
better understand impact individu differ efficaci medicin
first sequenc data collect variou site hospit research center privat
entiti larg divers popul china believ capabl quickli
produc larg amount data support collect data wuxi apptec
huawei launch china precis medicin cloud may huawei
inform commun technolog provid base china contribut
infrastructur cloud comput wuxi nextcod suppli platform
organ share genom data collect find volunt
sequenc genom easi part collect data use
gener clinic insight better understand diseas wont easi today
understand relev variou gene role diseas remain larg
portion genom lack clinic expertis
start assumpt total number genom sequenc part
chines pmi next five year attempt frame annual opportun
assum market share sequenc capac china would need
novaseq system individu novaseq cost around million averag
annual throughput impli annual consum opportun around
million million novaseq instrument revenu
genom sequenc share sequenc w/ throughput genom per complet placement per revenu per annual pull per pull-through annual revenu barclay illumina inc
believ drive faster earn growth revenu growth
time increas visibl high-teen better long-term ep growth
look back deliv averag revenu growth per year
translat averag ep growth recent year come despit
headwind grail helix dilut guid
revenu ep growth year
look back beat initi revenu forecast year
ep forecast year averag revenu upsid around translat ep
upsid versu initi guidanc addit year revenu out-
perform initi guidanc averag beat revenu ep
track record actual result vs initi guidanc
one natur lever higher margin consum servic
revenu continu grow percentag instal base
believ consum revenu reach total
drive annual margin improv overal illumina
favor given ramp-up
project growth clinic
translat market
growth china region
believ near-term outlook support number growth driver
research project clinic region growth china collect add
revenu growth coupl underli growth elast
demand believ enough lever off-set custom simpli look cost
save novaseq platform
increment research project ramp contribut least
collect annual growth next year
us us program sequenc genotyp patient
period sampl year ramp consum alon
add around annual sale year contribut addit
take novaseq instrument cater project improv visibl
regeneron plan sequenc exom biobank sampl
month period would repres total project consum
contribut per year revenu growth year
grail initi genom year period would add million
annual consum revenu growth
 growth clinic translat market add annual growth clinic
repres revenu believ sustain growth
volum shift broader panel growth oncolog beyond infecti diseas
 growth china add annual growth china repres illumina
revenu believ market sustain growth multipl year
believ china billion market
convict built around countri person medicin initi genom
complet period could add annual consum
revenu requir novaseq instrument instrument sale
near-term growth driver leav room upsid potenti forecast
sampl total con opp mm yearsannu con opp mm revgrowthcontribut growthu us research translat growth growth embed project ramp cost save barclay illumina inc
believ valuat
compel dcf
basi higher
convict given elast
demand survey
price target repres adj ep estim prior pt
base ebitda bn describ report thesi
built around compani abil gener mid-teen top-lin growth translat
high-teen better earn growth target multipl base histor
ratio earn growth project high-teen forseeabl futur
valuat analysi also support discount dcf analysi dcf
assum sustain double-digit revenu growth moder
per year thereaft build termin valu also assum
long-term ebitda margin vs final assum convert
ebitda cffo deploy around revenu toward capit expenditur
use wacc yield target price
illuminabarclay researchjack meehan cfa scenario analysi y/i y/i y/i y/i y/i adj net enterpris net share valu per net equiti share valu per tax ep adj valu per earn multipleev ebitda valuationdiscount dcf valuat barclay illumina inc
current trade compani averag
also trade premium life scienc tool peer though
histor trade richer premium
histor valuat price earn yr earn growth yr compound-annual-growth-rate
assumpt model place novaseq per year hiseq
hiseq decommiss persist beyond given multi-year adopt
util increas per novaseq end model
million survey averag sinc assum new custom add lower overal average
barclay research revenu build
segmentarray y/i miniseq instal y/i y/i stack y/i product y/i instrument instrument instrument instrument instrument miniseq instrument y/i y/i product product y/i product y/i servic y/i y/i barclay illumina inc
keep level innov high continu drive
elast demand
held high regard custom believ keep innov
high help continu drive elast demand extend illumina
advantag market research custom laugh ask
whether saw real competit threat market today estim
approxim illumina budget appli toward year
million size nearest competitor thermo fisher
level spend help improv convict stay forefront
innov long time beyond spend compani brand make
attract compani research scientist work final illumina ip
portfolio give competit moat believ continu expand compani
innov
research set sever advantag includ brand
qualiti scale custom reach compani scale expertis make
sought vendor research sometim even help custom
draft nih propos grant ensur access product servic
platform perspect abil scale high-throughput
sequenc unmatch competit final qualiti sequencing-by-
synthesi sb chemistri unlik supplant competit perhap
clinic sequenc still infanc believ market
transit way play hand time
advantag today start qualiti sb chemistri research view sb
gold standard determin mutat underli human diseas
includ singl nucleotid polymorph indel copi number variat
cnv addit diagnost move toward broader panel
drive share hand given abil gener higher-throughput
sequenc peer
fisherqiagen budget mmr toward budget barclay illumina inc
feedback custom competit environ
 domin clinic sequenc opportun
clinic opportun massiv much infanc
estim market billion analyst day see opportun
broaden tradit oncolog market microbiolog infecti diseas sexual
health beyond believ sever major competit advantag vs
peer though compani need move ahead aggress keep competitor
advantag start compani chemistri sb consid
gold standard determin mutat underli human diseas
convers lab director suggest altern long-read chemistri
still accur enough compet
similarli migrat toward broader panel play directli hand
given compani abil scale high-throughput platform thermo
fisher platform market today perform better target
sequenc base smaller panel believ everi major clinic sequenc
laboratori work today reason includ myriad genet
foundat medicin cover cover
brand make covet partner companion diagnost
develop recent partnership loxo bristol myer squibb highlight
abil drive growth cdx
customerwhat view competit environ ath bgi machin complet genom call bgi could realli compet novaseq europ distribut china might compet novaseq need taken serious follow consider cost advantag could captur market give price break mani consum buy kind like becom airlin reward member keep come back get better sequenc data produc done sequenc donli use use pacbio issu sequel high error rate per base great larg scaffold understand larg order structur error rate high allow character snv small indel current understand human biolog come addit cost per base order magnitud higher sequenc sequenc process much slower capac much lower per instrument neither sequel amen popul scale sequenc work great small number sampl want individu popul doesnt scale type number compani china realli cheap price sequenc develop strategi convinc custom perhap use sequenc spain eu usa given type servic get case bgi acquir complet genom multipl platform option offer coverag novaseq system custom tri oper cost either fund govern someth els ionli use jno one compet custom almost everi year buy new system barclay inc
said competitor discount compel valu
proposit offer laboratori
thermo fisher offer end-to-end workflow custom
sampl prep sequenc bioinformat believ need develop
comprehens bioinformat packag becom gold standard
industri obvious could monet
thermo fisher prais abil platform work well
final major competitor much greater scale diagnost today illumina
tradit use research platform great advantag
channel abl pivot platform clinic market easi task
though barrier entri reimburs technolog ease-of-us etc allow
make in-road
feedback custom potenti clinic sequenc
interview novaseq custom clearli demand interest
long-read sequenc technolog nanopor singl molecul sequenc
could potenti earn share custom wallet versu howev
time believ long-read supplement short-read technolog
work togeth differ advantag custom short-read technolog like
sequencing-by-synthesi sb chemistri highest qualiti consid
gold standard custom custom believ sb critic sequenc
technolog clinic set given abil detect singl nucleotid polymorph
copi number variat cnv indel underli human diseas said
long-read technolog provid advantag genom sequenc piec togeth
repetit area genom well non-human sampl plant given
brand custom relationship scale budget believ
compani potenti well posit penetr market time said
limit visibl close commerci actual
customerwhat view clinic sequenc need sequenc europ go increas next year money go novaseq good unless chines good think happen year would like get clinic space thing came across interest move sequenc diagnost tool rather research tool help kid nicu project that place got feel want play informat would tough bigger scale bigger team handl small number case scale would hard train enough peopl good clinic busi grow sampl per year jfor clinic move bigger bigger panel favor platform knovaseq make sequenc cheaper much money spend research pot fund novaseq tri get anoth pot clinic diagnost barclay inc
feedback custom demand long-rang sequenc
customerwhat view long-read sequenc a- care look pacbio sequel bionano sapphir nanopor also consid genet chromium machin far im concern realli look everyth year contempl buy machin nanopor say noth secret compani even custom like us nanopor unwis b- question structur variat short read technolog miss problem nanopor today high error rate use lot sequenc gener perform error correct around tough find cancer find structur variat go see displac present heard anyth nanopor center meet ceo noth murmur meet pretti mum thing readi let know cthe long read sequenc seemingli use posit price competit long time data nanopor human genom encourag project aggress increas yield gb price point data appl appl research give someth raw accuraci go one platform anoth today even total even per price would need addit sequenc price come could see interim situat data type use short accur read coupl nanopor long inaccur read could valuabl human genom nanopor thought neg month ago month ago start take much posit view theyv made lot progress make avail talk migrat clinic assay glong read realli get coupl novel area genom better understand long order structur genom potenti role structur human patholog diseas nanopor like higher capac per squar foot pacbio individu per base error rate still high make amend scaffold identif indel underli human diseas hhave look nanopor test think field today signific valu long read use pacbio sequel nanopor provid much longer read end day error rate high ihav look nanopor yet technolog realli new chose given brand name industri leader captur bulk market share industri situat littl competitor need evalu pacbio system error rate still somewhat high want someth better error rate complex system data analysi complex librari run favor novaseq joper nanopor sequenc absolut critic long-read sequenc certain project genom world wait long time long-read sequenc use long-read short read necessari de novo genom scaffold bacteri genom kit accur yet need readi case someth chang still need use conjunct technolog barclay inc
updat thought rang consum pull-through across
novaseq instrument place field rang broader
believ xp workflow impact novaseq util
expect custom shut instrument
next year across hiseq hiseq nextseq platform
manag risk flood instrument enter after-market
decommiss impact growth rate servic revenu
growth popul sequenc studi
trend see global fund environ research
could describ major popul sequenc initi expect
drive custom growth next year
rate genom sequenc biobank sampl trend
growth clinic translat custom
much budget go toward clinic solut
recent growth trend clinic translat custom
view lcd go drive demand clinic
set-up benefit opportun vs peer
could provid updat adopt iseq system thought
custom feedback whether clinic appropri set time
growth china market
manag competit risk china chines custom tri
disrupt market
china stand term precis medicin initi
china start purchas novaseq yet complet initi
move forward hiseq platform
look year china billion market
futur innov
mani lane theoret put novaseq flow cell time
thing drive genom
strategi enter market long-read sequenc
grow revenu double-digit sort earn leverag
drive
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
